Small Hospitals
Market Cap
₹6,188 ₹6,188 Cr.
P/E
80.53
PEG
2.49
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

The thesis comes alive only if planned treatment-volume growth converts from new and acquired capacity; capacity additions alone do not create revenue in this fixed-capacity business.

Bull path depends on a faster treatment-volume ramp combined with a stronger revenue-per-treatment mix, while bear path is triggered by treatment-volume underperformance alongside stagnant revenue per treatment.

Key revision triggers to watch include quarterly treatment growth, revenue per treatment, clinic additions, and the Andhra Pradesh PPP renewal outcome.

Get your Reports on Demand
Get detailed, analyst-grade reports with actionable insights to make informed investment decisions.
  Flat 20% OFF
 for Tijori Premium Users
  Flat 20% OFF  for Tijori Premium Users
5Y Revenue & EBITDA Estimates
KEY TRIGGERS TO WATCH
  • The thesis comes alive only if planned treatment-volume growth converts from new and acquired capacity; capacity additions alone do not create revenue in this fixed-capacity business.
  • Bull path depends on a faster treatment-volume ramp combined with a stronger revenue-per-treatment mix, while bear path is triggered by treatment-volume underperformance alongside stagnant revenue per treatment.
  • Key revision triggers to watch include quarterly treatment growth, revenue per treatment, clinic additions, and the Andhra Pradesh PPP renewal outcome.
Bear : 0.4% CAGR • ₹186 Cr
Base: 5.4% CAGR • ₹236 Cr
Bull: 9.5% CAGR • ₹286 Cr
Buy Report $5
Management Credibility Report
TRACK RECORD
  • Management earns trust on operational delivery: completed capacity additions and a continued rise in international-mix contribution were delivered, and no completed promise was fully missed.
  • The checkable financial targets both came in slightly below their implied levels, so financial guidance should be treated as approximate and shows a mild, not systematic, overstatement bias.
  • The core medium-term growth promise remains untested because the measurement window is unfinished and the company deliberately avoids annual guidance; credibility rests on near-term execution rather than forecasting.
Met : 2
Progress: 2
Missed : 0
Buy Report $5
WORST-CASE SCENARIO
  • The overall risk profile is dominated by governance and shareholder-structure concerns rather than operating or liquidity stress: a large expansion in share capital through CCPS conversions, bonus issuance and the IPO is the most severe red flag and presents the main existential shareholder-value risk.
  • The highest-severity external scenario is a combined India payer reset and captive-clinic insourcing shock that hits the hospital and government-linked revenue channels on which the model depends.
  • Beyond that, risk is concentrated in moderate accounting and business-model concerns—standalone versus consolidated profit divergence, rising credit-loss allowances, goodwill/PPA opacity, and customer and channel concentration—while cash generation and solvency are relative strengths.
High Risk : 1
Medium Risk : 8
Low Risk : 8
Buy Report $5
Powered By
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material